标题
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
作者
关键词
-
出版物
Cells
Volume 10, Issue 5, Pages 1225
出版商
MDPI AG
发表日期
2021-05-18
DOI
10.3390/cells10051225
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IDH1 mutations induce organelle defects via dysregulated phospholipids
- (2021) Adrian Lita et al. Nature Communications
- Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway
- (2021) Jinbiao Xiong et al. ACS Omega
- A vaccine targeting mutant IDH1 in newly diagnosed glioma
- (2021) Michael Platten et al. NATURE
- Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma
- (2021) Matthias Schneider et al. NEURO-ONCOLOGY
- Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas
- (2020) Wenxin Zeng et al. Cancer Cell International
- EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
- (2020) Nina Struve et al. ONCOGENE
- Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
- (2020) Hui Shi et al. International Journal of Nanomedicine
- Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway
- (2020) Wei Sun et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424
- (2020) Barbara J. Fisher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
- (2020) Matthew Gallitto et al. JOURNAL OF NEURO-ONCOLOGY
- Mechanisms and therapeutic implications of hypermutation in gliomas
- (2020) Mehdi Touat et al. NATURE
- Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
- (2020) Di Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
- (2020) Yang Liu et al. Cancers
- Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
- (2020) Hong-Qing Cai et al. Frontiers in Oncology
- Sirtuin activation targets IDH-mutant tumors
- (2020) Julie J Miller et al. NEURO-ONCOLOGY
- Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells
- (2020) Hiroaki Nagashima et al. Cancer Discovery
- Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
- (2020) Philip Dao Trong et al. Cells
- Considering the Experimental Use of Temozolomide in Glioblastoma Research
- (2020) Verena J. Herbener et al. Biomedicines
- Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment
- (2020) Elavarasan Subramani et al. CANCER RESEARCH
- Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies
- (2020) Matthew S Waitkus et al. CLINICAL CANCER RESEARCH
- Glutamine reliance in cell metabolism
- (2020) Hee Chan Yoo et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- TERT and DNMT1 expression predict sensitivity to decitabine in gliomas
- (2020) Jong-Whi Park et al. NEURO-ONCOLOGY
- PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency
- (2020) Ana Montaldi et al. ONCOLOGY REPORTS
- Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
- (2020) Lin Lin et al. Cancer Research and Treatment
- Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
- (2020) Yao Xiong et al. NEOPLASIA
- Sphingolipid Pathway as a Source of Vulnerability in IDH1mut Glioma
- (2020) Tyrone Dowdy et al. Cancers
- Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
- (2020) Victor Ruiz-Rodado et al. Cancer & Metabolism
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
- (2020) Michael Weller et al. Nature Reviews Clinical Oncology
- Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
- (2020) Clarissa Ribeiro Reily Rocha et al. Cells
- Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
- (2019) Paul Daniel et al. Frontiers in Oncology
- Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
- (2019) Paul Lesueur et al. BMC CANCER
- A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).
- (2019) Sani Haider Kizilbash et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
- (2019) Graham MacLeod et al. Cell Reports
- Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
- (2019) Philip Jonsson et al. CLINICAL CANCER RESEARCH
- Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide
- (2019) Anna-Laura Potthoff et al. Cancers
- Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells
- (2019) Massimo Romani et al. Cancers
- Comprehensive Prognostic and Predictive Molecular Subgroup Analysis within the High-risk Treatment Arms of NRG Oncology/RTOG 9802: a Phase III Trial of RT versus RT + PCV in High-risk Low-grade Gliomas
- (2019) E.H. Bell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
- (2019) Bryan G. Harder et al. MOLECULAR MEDICINE
- Longitudinal molecular trajectories of diffuse glioma in adults
- (2019) Floris P. Barthel et al. NATURE
- Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
- (2019) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
- (2019) Susan G. R. McDuff et al. Cancer Medicine
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity
- (2019) Fadi Jacob et al. CELL
- 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas
- (2018) Pavithra Viswanath et al. CANCER RESEARCH
- Procarbazine, lomustine and vincristine toxicity in low-grade gliomas
- (2018) G. Jutras et al. Current Oncology
- IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
- (2018) Mohammed Khurshed et al. FASEB JOURNAL
- Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas
- (2018) Lei Tang et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells
- (2018) Sanford Hsu et al. Oncotarget
- Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
- (2018) Samuel K. McBrayer et al. CELL
- PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells
- (2018) Naijie Liu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
- (2018) Alex Shimura Yamashita et al. NEURO-ONCOLOGY
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
- (2018) Shabierjiang JIAPAER et al. NEUROLOGIA MEDICO-CHIRURGICA
- ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
- (2018) Alice L. Yuan et al. PLoS One
- Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate
- (2018) Joseph P. Dexter et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence
- (2018) Giulia Allavena et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Low-Grade Glioma Radiotherapy Treatment and Trials
- (2018) Tony J.C. Wang et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide
- (2018) Iwona Anna Ciechomska et al. Frontiers in Pharmacology
- Targeting IDH1-Mutated Malignancies with NRF2 Blockade
- (2018) Yang Liu et al. JNCI-Journal of the National Cancer Institute
- Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics
- (2017) C. Izquierdo et al. JOURNAL OF NEURO-ONCOLOGY
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
- (2017) Sophie Weil et al. NEURO-ONCOLOGY
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
- (2017) Evanthia Galanis et al. NEURO-ONCOLOGY
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells
- (2017) Bing Li et al. Oncology Letters
- Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
- (2017) Georg Karpel-Massler et al. Nature Communications
- IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway
- (2017) Kaishu Li et al. Oncotarget
- PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
- (2017) Robert F. Koncar et al. Oncotarget
- Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells
- (2017) Barbara Banelli et al. Oncotarget
- Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
- (2017) Silvia Valtorta et al. Oncotarget
- Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours
- (2017) Remco J Molenaar et al. BMJ Open
- Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
- (2017) Alberto Azzalin et al. NEOPLASIA
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide
- (2016) Roy E. Strowd et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Brigitta G Baumert et al. LANCET ONCOLOGY
- Combine and conquer: challenges for targeted therapy combinations in early phase trials
- (2016) Juanita S. Lopez et al. Nature Reviews Clinical Oncology
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
- (2016) Wolfgang Wick et al. NEURO-ONCOLOGY
- Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma
- (2016) Hiroaki Nagashima et al. NEURO-ONCOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks
- (2016) Corinne Chabalier-Taste et al. Oncotarget
- Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis
- (2016) Tina Sehm et al. Oncotarget
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
- (2015) J. L. McFaline-Figueroa et al. CANCER RESEARCH
- IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
- (2015) J. L. Izquierdo-Garcia et al. CANCER RESEARCH
- Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51
- (2015) Ambber Ward et al. CANCER TREATMENT REVIEWS
- A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma
- (2015) Andra V. Krauze et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol-resistant glioma cells via inhibition of glucose metabolism
- (2015) DING-GUO GUAN et al. Molecular Medicine Reports
- Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide
- (2015) Yi Cui et al. MOLECULAR PHARMACEUTICS
- Brain tumour cells interconnect to a functional and resistant network
- (2015) Matthias Osswald et al. NATURE
- Insulator dysfunction and oncogene activation in IDH mutant gliomas
- (2015) William A. Flavahan et al. NATURE
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function
- (2015) LIANGYU CHEN et al. ONCOLOGY REPORTS
- A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells
- (2015) Anna-Maria Barciszewska et al. PLoS One
- DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status
- (2015) Adam Cohen et al. Acta Neuropathologica Communications
- Metabolic Reprogramming in Mutant IDH1 Glioma Cells
- (2015) Jose L. Izquierdo-Garcia et al. PLoS One
- 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
- (2015) Alexandra Borodovsky et al. Oncotarget
- Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
- (2015) Sevin Turcan et al. Oncotarget
- Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells
- (2015) Delphine Lamoral-Theys et al. NEOPLASIA
- Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression
- (2015) Benjamin Le Calvé et al. NEOPLASIA
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
- (2014) Chang Xia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance
- (2014) Shigeo Ohba et al. CANCER RESEARCH
- Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
- (2014) H. Wakimoto et al. CLINICAL CANCER RESEARCH
- A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres
- (2014) Alexandra Borodovsky et al. JOURNAL OF NEURO-ONCOLOGY
- Asparagine Plays a Critical Role in Regulating Cellular Adaptation to Glutamine Depletion
- (2014) Ji Zhang et al. MOLECULAR CELL
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Metformin—mode of action and clinical implications for diabetes and cancer
- (2014) Ida Pernicova et al. Nature Reviews Endocrinology
- Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy
- (2014) Encouse B. Golden et al. Neurosurgical Focus
- Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
- (2014) Fumiharu Ohka et al. TUMOR BIOLOGY
- Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
- (2014) Jinlong Shi et al. TUMOR BIOLOGY
- Unexpected low-dose toxicity of the universal solvent DMSO
- (2013) Joana Galvao et al. FASEB JOURNAL
- Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas
- (2013) Sriram Venneti et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Cerebral organoids model human brain development and microcephaly
- (2013) Madeline A. Lancaster et al. NATURE
- Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
- (2013) Johan Pallud et al. NEURO-ONCOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth
- (2013) Lei Wang et al. Nature Communications
- DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma
- (2012) Michael D. Blough et al. ANNALS OF NEUROLOGY
- Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
- (2012) H. A. Tawbi et al. ANNALS OF ONCOLOGY
- Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
- (2012) E. Q. Lee et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair
- (2012) Keiko Yata et al. MOLECULAR CELL
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
- (2012) Peppi Koivunen et al. NATURE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas
- (2012) A. Elkhaled et al. Science Translational Medicine
- Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions
- (2011) S Piaskowski et al. BRITISH JOURNAL OF CANCER
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
- (2011) Rasheduzzaman Chowdhury et al. EMBO REPORTS
- Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures
- (2011) Jihong Xu et al. JOURNAL OF NEURO-ONCOLOGY
- Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation
- (2011) Krista A. Van Nifterik et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
- (2011) Katherine E. Warren et al. JOURNAL OF NEURO-ONCOLOGY
- An in vivo patient-derived model of endogenous IDH1-mutant glioma
- (2011) H. A. Luchman et al. NEURO-ONCOLOGY
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
- (2011) G. Prasad et al. NEURO-ONCOLOGY
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
- (2011) Z. J. Reitman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
- (2010) Fonnet E. Bleeker et al. ACTA NEUROPATHOLOGICA
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
- (2010) M. J. Seltzer et al. CANCER RESEARCH
- Oligodendroglioma cell lines containing t(1;19)(q10;p10)
- (2010) J. J. P. Kelly et al. NEURO-ONCOLOGY
- The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation
- (2009) J. Portnow et al. CLINICAL CANCER RESEARCH
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Development ofin vitrosystems for nanotoxicology: methodological considerations
- (2009) Vicki Stone et al. CRITICAL REVIEWS IN TOXICOLOGY
- Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
- (2009) Jennifer A. Quinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Knocking Down Galectin 1 in Human Hs683 Glioblastoma Cells Impairs Both Angiogenesis and Endoplasmic Reticulum Stress Responses
- (2009) Marie Le Mercier et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
- (2009) Jennifer A. Quinn et al. NEURO-ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas
- (2008) A. Li et al. MOLECULAR CANCER RESEARCH
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
- (2008) Gaspar J. Kitange et al. NEURO-ONCOLOGY
- Mechanisms of Disease: temozolomide and glioblastoma—look to the future
- (2008) Maciej M Mrugala et al. Nature clinical practice. Oncology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started